Back to top
more

Anika Therapeutics (ANIK)

(Delayed Data from NSDQ)

$8.25 USD

8.25
85,508

-0.10 (-1.20%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.25 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study

by Zacks Equity Research

The FDA lifts partial clinical hold on Epizyme's lead pipeline candidate, tazemetostat's study.

    Zacks Equity Research

    FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program

    by Zacks Equity Research

    The FDA has lifted clinical hold on Sarepta's (SRPT) clinical study evaluating the Duchenne muscular dystrophy micro-dystrophin gene therapy program. The clinical hold was placed in July by the FDA.

      Zacks Equity Research

      Alexion Pharmaceuticals (ALXN) Surges: Stock Moves 5.3% Higher

      by Zacks Equity Research

      Alexion Pharmaceuticals (ALXN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

        Zacks Equity Research

        OPKO Health (OPK) Begins RAYALDEE Phase 2 Clinical Trial

        by Zacks Equity Research

        OPKO Health's (OPK) consistent focus on enhancing the efficacy of its flagship RAYALDEE platform is likely to lend it a competitive edge in the MedTech space.

          Zacks Equity Research

          Sesen Bio (SESN) Soars: Stock Adds 6.3% in Session

          by Zacks Equity Research

          Sesen Bio (SESN) shares rose more than 6% in the last trading session, amid huge volumes.

            Zacks Equity Research

            Retrophin (RTRX) Catches Eye: Stock Jumps 6.9%

            by Zacks Equity Research

            Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

              Zacks Equity Research

              Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 8% in Session

              by Zacks Equity Research

              Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

                Zacks Equity Research

                ANIK vs. ALKS: Which Stock Is the Better Value Option?

                by Zacks Equity Research

                ANIK vs. ALKS: Which Stock Is the Better Value Option?

                  Zacks Equity Research

                  Anika Reports Top Line Data from CINGAL Study, Shares Slump

                  by Zacks Equity Research

                  Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.

                    Zacks Equity Research

                    Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash

                    by Zacks Equity Research

                    The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.

                      Zacks Equity Research

                      Weakness Seen in Anika Therapeutics (ANIK) Estimates: Should You Stay Away?

                      by Zacks Equity Research

                      Anika Therapeutics (ANIK) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.

                        Zacks Equity Research

                        New Strong Sell Stocks for April 20th

                        by Zacks Equity Research

                        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                          Zacks Equity Research

                          New Strong Sell Stocks for April 16th

                          by Zacks Equity Research

                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                            Zacks Equity Research

                            New Strong Sell Stocks for April 6th

                            by Zacks Equity Research

                            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                              Zacks Equity Research

                              New Strong Sell Stocks for April 2nd

                              by Zacks Equity Research

                              Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                Zacks Equity Research

                                New Strong Sell Stocks for February 27th

                                by Zacks Equity Research

                                Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                  Zacks Equity Research

                                  Anika Therapeutics Receives FDA Nod for Bone Repair Therapy

                                  by Zacks Equity Research

                                  Anika Therapeutics' (ANIK) FDA approved HA-based injectable bone repair therapy provides a commercial edge to regenerative portfolio.

                                    Zacks Equity Research

                                    Anika (ANIK) Grows in Orthopedic Medicines on Positive Data

                                    by Zacks Equity Research

                                    Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.

                                      Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics

                                      by Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics

                                        Arpita Dutt headshot

                                        4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings

                                        by Arpita Dutt

                                        Here is a look at four drug stocks including Anika (ANIK) with a Sell Rank and negative earnings ESP that should be avoided ahead of earnings.

                                          Zacks Equity Research

                                          New Strong Sell Stocks for July 11th

                                          by Zacks Equity Research

                                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                            Zacks Equity Research

                                            Implied Volatility Surging for Anika Therapeutics (ANIK) Stock Options

                                            by Zacks Equity Research

                                            Options traders are pricing in a big move for Anika Therapeutics (ANIK) shares as it has huge implied volatility.

                                              Zacks Equity Research

                                              Novo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y

                                              by Zacks Equity Research

                                              Novo Nordisk A/S (NVO) reported fourth-quarter 2016 earnings of 50 cents per American Depository Receipt (ADR), missing the Zacks Consensus Estimate of 52 cents by 3.8%.

                                                Zacks Equity Research

                                                AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales

                                                by Zacks Equity Research

                                                AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.

                                                  Zacks Equity Research

                                                  AMAG Down Despite Positive Data on Makena Auto-Injector

                                                  by Zacks Equity Research

                                                  AMAG Pharmaceuticals (AMAG) announced positive top-line results from its pharmacokinetic (PK) study on Makena, subcutaneous auto-injector.